Search - tctmd.com

Displaying 1 - 20 of 96

Sort: Relevancy | Date

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News ACC 2023

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

L.A. McKeown

March 10, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

L.A. McKeown

March 09, 2023

News Conference News ACC 2023

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

Michael O'Riordan

March 09, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

Advertisement

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

What’s Going to Be Hot at ACC 2025?

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

What’s Going to Be Hot at ACC 2024

STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Managing AF Patients Undergoing PCI—Some Lingering Questions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content